Abstract: The present invention provides compounds of formula (I) where n, R1, R2, R3, R4, R5 and Heteroaryl are defined herein. The compounds are inhibitors of the uptake of one or more monoamines selected from serotonin, norepinephrine and dopamine and, as such, may be useful in the treatment of disorders of the central and/or peripheral nervous system.
Type:
Grant
Filed:
February 11, 2005
Date of Patent:
April 21, 2009
Assignee:
Eli Lilly and Company
Inventors:
Serge Louis Boulet, Barry Peter Clark, John Fairhurst, Peter Thaddeus Gallagher, Anette Margareta Johansson, Maria Ann Whatton, Virginia Ann Wood
Abstract: This invention relates to compounds of formula (I) where R1 to R12, —W—V—, —X—Y—, p and n have the values defined in claim 1, their preparation and use as pharmaceuticals for the treatment of central nervous system disorders, such as depression, bipolar disorder, and anxiety.
Type:
Grant
Filed:
December 6, 2002
Date of Patent:
February 26, 2008
Assignee:
Eli Lilly and Company
Inventors:
Javier Agejas-Chicharro, Graham Henry Timms, Andrew Caerwyn Williams, Nicholas Paul Camp, Jeremy Gilmore, Ana Belen Bueno Melendo, Carlos Lamas-Peteira
Abstract: This invention provides a novel series of non-peptidyl compounds which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical formulations which employ these novel compounds.
Type:
Grant
Filed:
June 5, 1995
Date of Patent:
April 27, 2004
Assignee:
Eli Lilly and Company
Inventors:
Sung Y. Cho, Thomas A. Crowell, Bruce D. Gitter, Philip A. Hipskind, J. Jeffry Howbert, Joseph H. Krushinski, Jr., Karen L. Lobb, Brian S. Muehl, James A. Nixon
Abstract: This invention provides a novel series of non-peptidyl compounds which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical formulations which employ these novel compounds.
Type:
Grant
Filed:
November 17, 1993
Date of Patent:
June 11, 2002
Assignee:
Eli Lilly and Company
Inventors:
Sung Y. Cho, Thomas A. Crowell, Bruce D. Gitter, Philip A. Hipskind, J. Jeffry Howbert, Joseph H. Krushinski, Jr., Karen L. Lobb, Brian S. Muehl, James A. Nixon
Abstract: A pharmaceutical compound of formula (I) in which R1 and R2 are each hydrogen or C1-4 alkyl, or R1 and R2 together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholino group, said group being optionally substituted with 1 to 3 C1-4alkyl substituents, R3 is a naphythyl, indolyl, benzothienyl, benzofuranyl, benzothiazolyl, quinolinyl or isoquinolinyl group, said group being optionally substituted, and n is 1 or 2; or a salt or ester thereof.
Type:
Grant
Filed:
October 3, 2001
Date of Patent:
May 7, 2002
Assignee:
Eli Lilly and Company
Inventors:
Martine Keenan, Sandra Ginette Milutinovic, David Edward Tupper
Abstract: This invention describes a novel rhesus monkey receptor having affinity for neuropeptide Y, pancreatic polypeptide, and peptide YY. This invention also encompasses nucleic acids encoding this receptor, or a fragment thereof, as well as methods employing this receptor and the nucleic acid compounds.
Abstract: The present invention provides a human glutamate receptor and related DNA compounds useful not only in assays for potential pharmaceuticals but also in methods for molecular biology techniques.
Type:
Grant
Filed:
March 7, 1995
Date of Patent:
November 6, 2001
Assignee:
Eli Lilly and Company
Inventors:
J. Paul Burnett, Nancy G. Mayne, Robert L. Sharp, Yvonne M. Snyder
Abstract: The present invention provides a human glutamate receptor and related DNA compounds useful not only in assays for potential pharmaceuticals but also in methods for molecular biology techniques.
Type:
Grant
Filed:
December 22, 1993
Date of Patent:
November 6, 2001
Assignee:
Eli Lilly and Company
Inventors:
J. Paul Burnett, Nancy G. Mayne, Robert L. Sharp, Yvonne M. Snyder
Abstract: This invention provides methods of treating secretory diarrhea or cystic fibrosis in a mammal which comprises administering to a mammal in need thereof an effective amount of diarylsulfonylurea. This invention also describes specific diarylsulfonylureas for use in treating secretory diarrhea or cystic fibrosis.
Abstract: This invention provides a series of substituted benzimidazoles which are useful in treating or preventing a condition associated with an excess of neuropeptide Y. This invention also provides methods employing these substituted benzimidazoles as well as pharmaceutical formulations with comprise as an active ingredient one or more of these compounds.
Type:
Grant
Filed:
January 9, 1997
Date of Patent:
July 3, 2001
Assignee:
Eli Lilly and Company
Inventors:
Thomas Charles Britton, Robert Frederick Bruns, Jr., Buddy Eugene Cantrell, Philip Arthur Hipskind, Karen Lynn Lobb, James Arthur Nixon, Paul Leslie Ornstein, Edward C. R. Smith, Hamideh Zarrinmayeh, Dennis Michael Zimmerman, Anne Marie Nunes, James Jeffry Howbert
Abstract: This invention provides novel benzylidene rhodanines which are useful as agents in treating or preventing conditions associated with &bgr;-amyloid peptide. This invention further provides methods of treating or preventing Alzheimer's Disease which comprises administering to a mammal in need thereof an effective amount of one or more of the benzylidene rhodanines of the present invention.
Type:
Grant
Filed:
March 16, 1994
Date of Patent:
June 26, 2001
Assignee:
Eli Lilly and Company
Inventors:
Jill A. Panetta, Michael L. Phillips, Jon K. Reel, John K. Shadle, Sandra K. Sigmund, Richard L. Simon, Celia A. Whitesitt
Abstract: This invention provides a series of substituted indoles which are useful in treating or preventing a condition associated with an excess of neuropeptide Y. This invention also provides the novel substituted indoles as well as pharmaceutical formulations with comprise as an active ingredient one or more of these substituted indoles.
Type:
Grant
Filed:
August 29, 1996
Date of Patent:
June 12, 2001
Assignee:
Eli Lilly and Company
Inventors:
Thomas C. Britton, Robert F. Bruns, Jr., Donald R. Gehlert, Philip A. Hipskind, Karen L. Lobb, James A. Nixon, Paul L. Ornstein, Edward C. R. Smith, Hamideh Zarrinmayeh, Dennis M. Zimmerman
Abstract: This invention describes a novel rhesus receptor having affinity for neuropeptide Y, pancreatic polypeptide, and peptide YY. This invention also encompasses nucleic acids encoding this receptor, or a fragment thereof, as well as methods employing this receptor and the nucleic acid compounds.
Abstract: This invention describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering an analog of an obesity protein. This invention further describes methods of treating conditions associated with an excess of neuropeptide Y which coomprises administering an analog of an obesity protein in combination with a neuropeptide Y antagonist. This invention demonstrates that the obesity protein acts by reducing the production of neuropeptide Y by the hypothalamus.
Type:
Grant
Filed:
June 28, 1996
Date of Patent:
April 24, 2001
Assignee:
Eli Lilly and Company
Inventors:
Juliana Maude Bue-Valleskey, Mark Louis Heiman, Thomas Wesley Stephens, Frank C. Tinsley
Abstract: This invention provides certain substituted benzenesulfonamide derivatives and methods for using them in the treatment of susceptible neoplasms in mammals. Also provided are certain novel pharmaceutical formulations employing these benzenesulfonamide derivatives in combination with a carrier.
Type:
Grant
Filed:
March 29, 1999
Date of Patent:
January 16, 2001
Assignee:
Eli Lilly and Company
Inventors:
William J Ehlhardt, James E Ray, John E Toth
Abstract: This invention provides a series of substituted 2-imidazolines which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical formulations which employ these compounds.
Type:
Grant
Filed:
June 10, 1994
Date of Patent:
January 16, 2001
Assignee:
Eli Lilly and Company
Inventors:
Philip A. Hipskind, J. Jeffry Howbert, Brian S. Muehl
Abstract: This invention provides methods for the treatment or prevention of interstitial cystitis or urethral syndrome in a mammal which comprise administering to a mammal in need thereof an effective amount of duloxetine.
Type:
Grant
Filed:
September 8, 1998
Date of Patent:
November 21, 2000
Assignee:
Eli Lilly and Company
Inventors:
Smriti Iyengar, Mark A. Muhlhauser, Karl B. Thor
Abstract: This invention provides certain sulfonamide compounds, formulations, and a method for treating susceptible neoplasms in mammals using certain sulfonamide compounds.
Type:
Grant
Filed:
March 24, 1993
Date of Patent:
November 14, 2000
Assignee:
Eli Lilly and Company
Inventors:
Thomas A. Crowell, J. Jeffry Howbert, John S. Ward
Abstract: The invention provides a novel phospholipase A.sub.2 enzyme, polynucleotides encoding such enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.
Type:
Grant
Filed:
March 20, 1998
Date of Patent:
August 15, 2000
Assignee:
Eli Lilly and Company
Inventors:
Ruth Maria Kramer, Richard Todd Pickard, John David Sharp, Beth Ann Strifler
Abstract: This invention describe a novel human amyloid precursor protein protease; nucleic acids encoding the protease; and methods employing the protease, as well as methods employing the nucleic acids encoding the protease.
Type:
Grant
Filed:
October 2, 1997
Date of Patent:
July 25, 2000
Assignee:
Eli Lilly and Company
Inventors:
Eric P Dixon, Edward M. Johnstone, Sheila P. Little